Skip to main content

FDA Approvals

FDA Approvals
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Loretta Fala
Read More
FDA Approvals
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation
Loretta Fala
Read More
FDA Approvals
Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Yonsa (Fine-Particle Abiraterone Acetate) New Formulation Approved for Metastatic Prostate Cancer
Loretta Fala
Read More
FDA Approvals, Payers' Guide
Welcome to the Tenth Annual Payers’ Guide to New FDA Approvals
Read More
Payers' Guide, FDA Approvals
Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin Approved for Relapsed or Refractory Hairy-Cell Leukemia
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Nuzyra (Omadacycline) Approved for the Treatment of Community-Acquired Bacterial Pneumonia or Acute Bacterial Skin and Skin Structure Infections
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination FDA Approved for the Treatment of Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh
Read More
Page 23 of 53
Results 221 - 230 of 524